Celltrion's Steqeyma completes rollout in major European markets, intensifying competition in the ustekinumab market. FDA approved Steqeyma in December 2024 for inflammatory conditions ...

Switching from ustekinumab to biosimilar SB17 maintains long-term efficacy and safety in psoriasis patients, supporting cost-effective treatment options. A phase 3 trial with 503 participants ...

Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously ...

While speaking at the conference, J&J’s CEO, Joaquin Duato, indicated the company’s willingness to protect Stelara, its branded anti-interleukin (IL)-12/23 biologic, against sales erosion from ...

Stelara (ustekinumab) is a brand-name injectable drug prescribed for certain autoimmune conditions. Stelara has interactions with some other drugs and certain vaccines. Examples include Orencia ...

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term comparable efficacy and safety up to week 52. Patients with psoriasis who switched ...

It will compete with other biologic therapies for Crohn's, including J&J's IL-12 and IL-23 inhibitor Stelara (ustekinumab), Takeda's Entyvio (vedolizumab) and Biogen's Tysabri (natalizumab ...

No clinically meaningful differences were observed in the efficacy, safety, pharmacokinetics, and immunogenicity of proposed biosimilar and ustekinumab for the treatment of moderate to severe plaque ...

Will the Stelara biosimilars be a reprise of the Humira biosimilars in 2023 and be slow to catch on? Biosimilar watchers circled 2023 as a red-letter year because that was the year that the Humira ...